Safety And Efficacy Of Chimeric Antigen Receptor T Cells Modified To Target Mesothelin And Express Pd-1 Antibodies In Patients With Relapsed/Refractory Solid Cancers In A Phase I Trial.
JOURNAL OF CLINICAL ONCOLOGY(2020)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要